 | Analysts Anticipate Halozyme Therapeutics, Inc. (NASDAQ:HALO) Will Announce Earnings of $0.32 Per Share americanbankingnews.com - March 4 at 10:16 PM |
 | Let's Take Another Look at Halozyme Therapeutics finance.yahoo.com - March 4 at 5:09 PM |
 | 2 Overvalued Biotech Stocks Still Worth Buying finance.yahoo.com - March 4 at 7:04 AM |
 | Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 6.8% americanbankingnews.com - March 3 at 8:06 PM |
 | Helen Torley Sells 50,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock americanbankingnews.com - March 1 at 10:04 PM |
 | Michael J. Labarre Sells 18,324 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock americanbankingnews.com - March 1 at 10:04 PM |
 | Kenneth J. Kelley Sells 5,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock americanbankingnews.com - March 1 at 9:32 PM |
 | Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8% americanbankingnews.com - February 25 at 9:18 PM |
 | Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027 finance.yahoo.com - February 24 at 11:11 PM |
 | Why Halozyme Therapeutics Is Trading 14% Higher Today fool.com - February 24 at 3:45 PM |
|
 | Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls nasdaq.com - February 24 at 1:10 PM |
 | Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High at $55.55 americanbankingnews.com - February 24 at 11:01 AM |
 | Halozyme Therapeutics Inc (HALO) Q4 2020 Earnings Call Transcript fool.com - February 23 at 10:44 PM |
 | Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results finance.yahoo.com - February 23 at 7:55 PM |
 | Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027 finance.yahoo.com - February 23 at 7:55 PM |
 | Recap: Halozyme Therapeutics Q4 Earnings finance.yahoo.com - February 23 at 7:55 PM |
 | Halozyme Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation seekingalpha.com - February 23 at 7:34 PM |
 | Halozyme Therapeutics's Earnings: A Preview finance.yahoo.com - February 22 at 1:30 PM |
 | Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call finance.yahoo.com - February 10 at 5:57 PM |
 | Antidiabetics Market (Impact of COVID-19) Size, Status and Forecast 2020-2025 marketwatch.com - February 9 at 8:01 PM |
 | Halozyme Therapeutics (NASDAQ:HALO) Hits New 1-Year High at $51.28 americanbankingnews.com - February 9 at 10:44 AM |
 | Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis finance.yahoo.com - January 16 at 4:20 AM |
 | First Week of September 17th Options Trading For Halozyme Therapeutics (HALO) nasdaq.com - January 15 at 12:50 PM |
 | Regeneron (REGN), U.S. Government Ink Deal for COVID-19 Treatment finance.yahoo.com - January 13 at 6:12 PM |
 | Sarepta (SRPT) Looks Good: Stock Adds 9.1% in Session msn.com - January 12 at 1:42 PM |
 | Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth finance.yahoo.com - January 11 at 9:57 AM |
 | Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 4 at 9:18 AM |
 | A Technical Update on Halozyme Therapeutics finance.yahoo.com - December 23 at 4:05 PM |
 | Breast Cancer Therapeutics Drugs Market 2021 Growth After Covid-19 Pandemic with Top Manufacturers: Bayer HealthCare, Eli Lily, Pfizer benzinga.com - December 22 at 8:49 AM |
 | Is Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) 22% ROE Better Than Average? finance.yahoo.com - December 19 at 12:45 PM |
|
 | Why These 3 Health Care Stocks Are Moving Today benzinga.com - December 17 at 1:47 PM |
 | Halozyme Therapeutics (NASDAQ:HALO) Now Covered by Analysts at Berenberg Bank americanbankingnews.com - December 17 at 8:44 AM |
 | Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy? finance.yahoo.com - December 16 at 1:46 PM |
 | Viatris (VTRS) to Cut Jobs as Part of Restructuring Initiative finance.yahoo.com - December 14 at 5:41 PM |
 | Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND finance.yahoo.com - December 8 at 4:35 PM |
 | Halozyme: 7 Years Of Royalty Bliss Coming; Afterwards, Questions To Answer seekingalpha.com - December 7 at 2:48 AM |
 | Halozyme Therapeutics Is Likely to Continue Its Advance finance.yahoo.com - December 4 at 5:11 PM |
 | Why Is Halozyme Therapeutics (HALO) Up 28.4% Since Last Earnings Report? finance.yahoo.com - December 2 at 4:58 PM |
 | What Makes Halozyme Therapeutics (HALO) a Strong Momentum Stock: Buy Now? finance.yahoo.com - November 27 at 1:47 PM |
 | A Look Into Halozyme Therapeutics's Debt finance.yahoo.com - November 23 at 1:52 PM |
 | Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE ® Technology businesswire.com - November 23 at 8:51 AM |
 | Halozyme raises FY20 guidance on Horizon Therapeutics global collaboration seekingalpha.com - November 23 at 8:51 AM |
 | Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology finance.yahoo.com - November 23 at 8:51 AM |
 | Halozyme Raises Full Year 2020 Guidance finance.yahoo.com - November 23 at 8:51 AM |
 | Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference finance.yahoo.com - November 18 at 8:44 PM |
 | Wells Fargo Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $60 benzinga.com - November 17 at 10:54 PM |
 | Thinking about trading options or stock in Ford, Draftkings, Li Auto, Vipshop Holdings, or Halozyme Therapeutics? prnewswire.com - November 13 at 1:13 PM |
 | Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer finance.yahoo.com - November 13 at 1:13 PM |
 | Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO™/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma finance.yahoo.com - November 12 at 1:09 PM |
 | Stock Alert: Halozyme Therapeutics Gains 10% nasdaq.com - November 6 at 1:33 PM |